October 28, 2008

Announcement of New Shares by Third Party Allocation TSD Japan, Inc.("TSD") is pleased to announce that it has completed the issuance of new stock by third party allocation in the amount of 800,220,000 yen. The financing was mainly led by venture capitals, Daiwa SMBC Capital Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., COLLABO SANGAKUKAN, Sansei Capital Investment Co., Ltd., Osaka Small and Medium Business Investment & Consultation Co., Ltd, IkeGin Capital Co., Ltd, Bio-Sight Capital, Inc. and a business corporation, AnGes MG, Inc. We believe their decision on investing in TSD despite the severe situation surrounding pharmaceutical venture companies came from their recognition and expectations toward our business. Therefore, we will commit to make our best efforts to fulfill their expectations by steadily expanding business. The funds will be allocated for development of COLAL-PRED®, treatment for ulcerative colitis, and HVJ-E, anti-prostate cancer agent.

TSD Japan, Inc.
Head Office	:	1-15-2 Nishinakajima, Yodogawa-ku, Osaka, Japan
President & CEO	:	Yoshiharu Sakashita
Date Established	:	July 2005
Capital Stock	:	734 million yen (as of October 28, 2008)
Main Business	:	1. Value-added type partnering business to assist partnering     between domestic and foreign bio-venture companies and     pharmaceutical companies in Japan 2. Support Clinical Trials and Develop own Products service(CRO Business)

For more information please contact:
TSD Japan, Inc.
1-15-2 nishinakajima, Yodogawa-ku, Osaka
TEL +81-6-6309-5200 FAX +81-6-6309-5203


081028 Press Release


back